Evidence map›Paper›PMID 25255454›Full record

ArticlePLoS pathogens2014

Out-of-sequence signal 3 as a mechanism for virus-induced immune suppression of CD8 T cell responses.

Stina L Urban, Raymond M Welsh

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. STAT3 Role in T-Cell Memory Formation.International journal of molecular sciences · 2022
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Disease-promoting effects of type I interferons in viral, bacterial, and coinfections.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2015
    Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Stina L UrbanDepartment of Pathology, Immunology and Virology Program, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
Raymond M WelshDepartment of Pathology, Immunology and Virology Program, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
University of Massachusetts Chan Medical School · US

Funding

Virology and Technology CoreP01AI046629 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI GREINER, DALE LESLIE · 1999 to 2014
$19.1M
PILOT AND FEASIBILITY PROGRAMP30DK032520 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI CZECH, MICHAEL P · 1986 to 2010
$14.6M
RESEARCH TRAINING IN INFECTIOUS DISEASEST32AI007343 · NIAID · UNIVERSITY OF IOWA · PI STAPLETON, JACK T. · 1988 to 2024
$5.0M
TRAINING IN IMMUNOLOGY (COMPETITIVE RENEWAL OF AI07439)T32AI007349 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI STERN, LAWRENCE J. · 1989 to 2024
$4.5M
Immunity and Virus DiseaseR37AI017672 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI WELSH, RAYMOND M · 2004 to 2013
$4.0M
Virus induced immunopathologyR01AI081675 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI WELSH, RAYMOND M · 2009 to 2013
$2.0M
IMMUNITY AND VIRUS DISEASER01AI017672 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI WELSH, RAYMOND M · 1985 to 2003
$1.4M
NIAID NIH HHS AI007349NIAID NIH HHS AI017672NIAID NIH HHS AI046629NIAID NIH HHS AI081675NIAID NIH HHS P01 AI046629NIAID NIH HHS R01 AI017672NIAID NIH HHS R01 AI081675NIAID NIH HHS R37 AI017672NIAID NIH HHS T32 AI007343NIAID NIH HHS T32 AI007349NIDDK NIH HHS DK32520NIDDK NIH HHS P30 DK032520
6 · The paper itself

Abstract

Virus infections are known to induce a transient state of immune suppression often associated with an inhibition of T cell proliferation in response to mitogen or cognate-antigen stimulation. Recently, virus-induced immune suppression has been linked to responses to type 1 interferon (IFN), a signal 3 cytokine that normally can augment the proliferation and differentiation of T cells exposed to antigen (signal 1) and co-stimulation (signal 2). However, pre-exposure of CD8 T cells to IFN-inducers such as viruses or poly(I∶C) prior to antigen signaling is inhibitory, indicating that the timing of IFN exposure is of essence. We show here that CD8 T cells pretreated with poly(I∶C) down-regulated the IFN receptor, up-regulated suppressor of cytokine signaling 1 (SOCS1), and were refractory to IFNβ-induced signal transducers and activators of transcription (STAT) phosphorylation. When exposed to a viral infection, these CD8 T cells behaved more like 2-signal than 3-signal T cells, showing defects in short lived effector cell differentiation, reduced effector function, delayed cell division, and reduced levels of survival proteins. This suggests that IFN-pretreated CD8 T cells are unable to receive the positive effects that type 1 IFN provides as a signal 3 cytokine when delivered later in the signaling process. This desensitization mechanism may partially explain why vaccines function poorly in virus-infected individuals.

Indexed as

Immunosuppression TherapyAnimalsBlotting, WesternCD8-Positive T-LymphocytesCells, CulturedInterferon Type ILymphocyte ActivationLymphocytic ChoriomeningitisLymphocytic choriomeningitis virusMaleMiceMice, Inbred C57BLPhosphorylationPoly I-CReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionInterferon Type IPoly I-CRNA, MessengerSocs1 protein, mouseSuppressor of Cytokine Signaling 1 ProteinSuppressor of Cytokine Signaling Proteins

Identifiers

PMID25255454
PMCPMC4177909
OpenAlexW2037457284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.